Replies to post #171434 on Biotech Values

[DewDiligence]

Curious that Samsung Bioepis is pursuing Remicade and Enbrel FoB's in Europe, but apparently not Humira. Anyone care to speculate why?

[DewDiligence]

EMA accepts Enbrel FoB from Samsung Bioepis for review:

http://finance.yahoo.com/news/european-medicines-agency-accepts-samsung-140000298.html

Samsung Bioepsis is a JV of BIIB and Samsung (#msg-69629103) that has a partnership arrangement with MRK on certain (undisclosed) FoB programs (#msg-84781042).

Samsung Bioepsis is also developing a Remicade FoB.

[DewDiligence]

MRK-Samsung/BIIB*—Phase-3 trials for Enbrel and Remicade FoBs met primary endpoint:

http://finance.yahoo.com/news/merck-samsung-bioepis-announce-pivotal-124600445.html

The five FoBs in this collaboration are:

• Enbrel [worldwide except US/EU/Japan]
• Remicade [worldwide except EU/Russia/Turkey]
• Humira [worldwide except EU/Russia/Turkey]
• Herceptin [worldwide]
• Lantus [worldwide]

Samsung Bioepis is conducting the trials in all of the above programs except Lantus, where MRK has the lead role.

*d/b/a Samsung Bioepis.